NewsRx

Search our medical news database

Tumor Suppression

Novel agent SI-27 halts angiogenesis in laboratory studies

Published in Cancer Weekly, May 14th, 2002

by Sonia Nichols, senior medical writer - Laboratory studies show a novel agent, SI-27, can block angiogenesis by limiting enzymatic activity.

SI-27 has been tested on human endothelial cells at Tokyo, Japan's Nippon Medical School. Those test results show SI-27 prevents angiogenesis by blocking matrix metalloproteinases (MMPs), or enzymes that degrade extracellular proteins. Because of this specificity, SI-27 holds the potential for being a useful therapy for selected diseases caused by pathologic angiogenesis.

Daizo Yoshida and associates in the Department of Neurosurgery coauthored the study with colleagues in the Central Institute for Electron...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook